FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to crystalline citrate of 9E-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triazatetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene (Compound I), a based pharmaceutical composition, a method of treating using the compound and using it for treating proliferative diseases.
EFFECT: compound
exists in the single polymorphic form and has the improved properties of stability; it is non-hygroscopic and insoluble in organic solvents.
15 cl, 8 tbl, 23 dwg, 12 ex
| Title |
Year |
Author |
Number |
| 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE |
2009 |
- Dimok Brajan
- Li Chehn Khsia Andzhelina
- Vil'Jam Ehntoni Deodaunija
|
RU2527970C2 |
| SALTS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASE |
2013 |
- Laj Mej
- Vitovski Stiven Richard
- Tester Richland Vejn
- Li Kvangkho
|
RU2711077C2 |
| NOVEL CRYSTALLINE FORMS OF N-[-2[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6-{[(1R,2S)-2,3-DIHYDROXY-1-METHYLPROPYL]OXY}-4-PYRIMIDINYL]-1-AZATIDINE-SULPHONAMIDE |
2011 |
- Gullberg Britt Anne Ingela
- Larsson Peter Thomas
- Stonehouse Jeffrey Paul
|
RU2548044C2 |
| SOLID FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR |
2013 |
|
RU2673077C2 |
| CRYSTALLINE SOLVATES OF HYDROCHLORIDE 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE |
2012 |
- Nagel Norbert
- Baumgartner Bruno
- Berkhtold Kharald
- Plettenburg Oliver
- Kaderajt Diter
- Monikke Mandi
- Gessler Zimon
- Tillner Joakhim
|
RU2619129C2 |
| SOLID FORMS OF CEFTOLOZANE |
2014 |
- Khvang Yu Seok
- Damur Nikol Miller
- Duong Liza
- Yurkauskas Valdas
- Mosos Kristos Adrian
- Mudur Sandzhaj
- Ovat Asli
- Terrachchano Dzhozef
- Vurtink Yason
|
RU2703457C2 |
| METHOD OF PRODUCING N-[5-(3,5-DIFTORBENZIL)-1H-INDAZOLE-3-YL]-4-(4-METHYLPIPERAZINE-1-YL)-2-(TETRAHYDROPYRAN-4-YLAMINO)BENZAMIDE |
2013 |
- Barbudzhan Natale Alvaro
- Forino Romualdo
- Orsini Paolo
|
RU2602071C2 |
| NOVEL SOLID FORMS (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID |
2020 |
- Jensen, Klaus, Gervig
- Jorgensen, Morten
- Dzhukhl, Martin
- Kvaerno, Lisbet
- De Diego, Khejdi, Lopez
- Fredkholt, Karin
- Terkelsen, Frans Dennis
- Frikhed, Tobias Gilling
- Yakobsen, Mikkel Fog
|
RU2820501C2 |
| 1-[4-[1-(4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO)ETHYL]-2-ETHYL BENZYL]AZETIDINE-3-CARBOXYLIC ACID HEMIFUMARATE SALT |
2009 |
- Lekh Tsizhevski
- Mehrilin De-La-Krus
- P'Otr Kh. Karpinski
- Mikhaehl' Mutts
- Kristian Riger
- Kaspar Fogel'
- Rikardo Shneberger
|
RU2518114C2 |
| POLYMORPHIC MODIFICATIONS OF N-[(3-FLUORO-4-METHOXYPYRIDINE-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({ 4-[(2-OXOPYRIDINE-1-YL)METHYL]PHENYL} METHYL)PYRAZOLE-4-CARBOXAMIDE AND THEIR SALTS |
2017 |
- Beaton, Haydn
- Crowe, David Malcolm
- Edwards, Hannah Joy
- Griffiths-Haynes, Nicholas James
|
RU2756273C2 |
